14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia

Schizophrenia Spectrum Disorders: Phenomenology & Neurobiology

Schizophrenia is a severe, chronic neurodevelopmental psychiatric disorder characterized by profound disruptions in perception, thought processing, emotional expression, and social functioning. Understanding the functional anatomy of central dopaminergic pathways provides the rational framework for both symptom phenomenology and antipsychotic pharmacology.

Dopaminergic Pathways & Clinical Correlation

1. Mesolimbic Pathway (Ventral Tegmental Area to Nucleus Accumbens): Dopaminergic hyperactivity in this tract mediates the positive symptoms of psychosis (auditory hallucinations, delusions, paranoia, conceptual disorganization). Antipsychotic blockade of D2 receptors in this pathway suppresses positive symptoms.
2. Mesocortical Pathway (Ventral Tegmental Area to Prefrontal Cortex): Dopaminergic hypofunction in the dorsolateral and ventromedial prefrontal cortex mediates the negative symptoms (avolition, alogia, affective flattening, anhedonia) and cognitive executive deficits. First-generation D2 blockers can inadvertently worsen negative symptoms in this pathway.
3. Nigrostriatal Pathway (Substantia Nigra Pars Compacta to Caudate/Putamen): Modulates motor control and the basal ganglia loop. D2 receptor antagonism here produces extrapyramidal symptoms (EPS) and, with chronic use, tardive dyskinesia.
4. Tuberoinfundibular Pathway (Hypothalamus to Anterior Pituitary): Dopamine acts tonically as Prolactin-Inhibiting Factor. Blockade of D2 receptors disinhibits prolactin secretion, resulting in hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction).

Schneiderian First-Rank Symptoms

Kurt Schneider identified key psychotic phenomena that, while not entirely pathognomonic, strongly point toward schizophrenia in the absence of an organic toxic state:

• Auditory Hallucinations: Voices heard arguing with one another; voices providing a continuous running commentary on the patient's ongoing actions, thoughts, or movements; or thoughts heard spoken aloud (Gedankenlautwerden / thought echo).
• Delusions of Passivity / Control: The belief that one's somatic sensations, impulses, feelings, or motor volitions are directly manipulated or controlled by an external agency or force.
• Thought Alienation:
  • Thought Insertion: Belief that thoughts are being placed directly into the mind from an outside source.
  • Thought Withdrawal: Belief that thoughts are being stolen or actively extracted from the mind by external forces.
  • Thought Broadcasting: Belief that one's private thoughts are radiating escape into the public domain so that others can hear them.
• Delusional Perception: A normal real-world sensory perception is interpreted with immediate, delusional, highly self-referential meaning (e.g., a green traffic light signifies that the patient has been anointed by extraterrestrial royalty).

DSM-5 Diagnostic Criteria & Spectrum Categorization

Diagnosis requires at least 2 of the following 5 symptoms, each active for a significant portion of time during a 1-month active phase (or less if successfully treated), with at least one of the symptoms being (1), (2), or (3):

1. Delusions (fixed, false idiosyncratic beliefs unshakeable by rational evidence or cultural consensus)
2. Hallucinations (sensory perceptions in the absence of an external stimulus, predominantly auditory)
3. Disorganized Speech (formal thought disorder: derailment, loose associations, neologisms, word salad)
4. Grossly Disorganized or Catatonic Behavior (purposeless agitation, bizarre posturing, waxy flexibility, mutism)
5. Negative Symptoms (diminished emotional expression, avolition, alogia, anhedonia, asociality)

Chronological Classifications on the Psychotic Spectrum:

• Brief Psychotic Disorder: Symptom duration of at least 1 day but less than 1 month, followed by a complete return to premorbid functioning (often precipitated by acute catastrophic psychosocial trauma).
• Schizophreniform Disorder: Full clinical criteria for schizophrenia met, but the total duration of disturbance (including prodromal, active, and residual phases) is at least 1 month but less than 6 months.
• Schizophrenia: Continuous signs of disturbance persisting for at least 6 months, including at least 1 month of active-phase symptoms, causing significant socio-occupational or self-care dysfunction.
• Schizoaffective Disorder: An uninterrupted period of illness during which there is a major mood episode (major depressive or manic) concurrent with active symptoms of schizophrenia, preceded or followed by at least 2 weeks of delusions or hallucinations in the absence of a major mood episode. Major mood episodes must occupy most of the total active and residual illness; otherwise schizophrenia with mood episodes is more likely. The 2-week psychosis-without-mood interval distinguishes schizoaffective disorder from mood disorders with psychotic features.

---

Differential Diagnosis: Acute Delirium vs. Dementia vs. Schizophrenia

Distinguishing delirium from primary psychiatric psychosis and underlying dementia is among the most consequential diagnostic tasks in hospital medicine. Misdiagnosing delirium as schizophrenia leads to inappropriate psychotropic sedation while life-threatening systemic illness progresses unchecked.

The Clinical Evaluation of Delirium

• Pathophysiological Cascade: Diffuse cerebral cortical and subcortical microvascular dysfunction driven by neuroinflammation, systemic cytokine storms (IL-1, IL-6, TNF-alpha), oxidative stress, and a central neurotransmitter imbalance characterized by profound acetylcholine deficiency and relative dopaminergic excess.
• The PINCH ME Mnemonic for Delirium Precipitants:
  • P – Pain: Severe unmanaged acute post-surgical, ischemic, or musculoskeletal pain.
  • I – Infection: Urinary tract infections (especially in catheterized elderly patients), pneumonia, sepsis, meningitis/encephalitis.
  • N – Nutrition / Dehydration: Hypovolemia, starvation, severe malnutrition, thiamine deficiency.
  • C – Constipation / Retention: Fecal impaction, urinary retention from prostatic hypertrophy or anticholinergic drugs.
  • H – Hypoxia / Hypoperfusion: Respiratory failure, congestive heart failure, acute myocardial infarction, severe anemia, stroke.
  • M – Medication: Polypharmacy, anticholinergic agents (oxybutynin, diphenhydramine, TCAs), sedatives/hypnotics, opioids, or acute substance withdrawal (alcohol, benzodiazepines).
  • E – Electrolyte & Endocrine: Hyponatremia, hypercalcemia, hypoglycemia, diabetic ketoacidosis, uremic encephalopathy, hepatic encephalopathy.
• Diagnostic Tool – The Confusion Assessment Method (CAM): Requires the presence of:
  1. Acute Onset and Fluctuating Course (demonstrated by history from staff or family), AND
  2. Inattention (difficulty focusing; cannot recite days of week backwards or spell 'WORLD' backwards),
  • PLUS EITHER:
  1. Disorganized Thinking (incoherent speech, tangential thinking), OR
  2. Altered Level of Consciousness (hyperactive, lethargic, stuporous).
• Management Principles in Delirium: Identify and eliminate underlying causes. First-line therapy is strictly non-pharmacological: regular reorientation (visible clocks, calendars), stable daylight exposure, presence of family members, provision of sensory aids (glasses, hearing aids), and avoidance of physical restraints. If distress or dangerous agitation persists despite de-escalation, consider short-term low-dose haloperidol (e.g. 0.5–1 mg PO/IM, usually <=1 week), with frequent review. Check ECG/electrolytes and avoid it in Parkinson disease, Lewy body dementia or relevant QT contraindications; use the lowest effective dose. Benzodiazepines are strictly avoided as they reliably exacerbate delirium, with the sole exception of delirium caused by alcohol or sedative-hypnotic withdrawal.

Key Dementia Subtypes in Regional Medicine

• Alzheimer's Disease: Characterized by extracellular amyloid-beta plaques and intracellular hyperphosphorylated tau neurofibrillary tangles; early prominent episodic short-term memory loss followed by apraxia, agnosia, and executive decline.
• Vascular Dementia: Second most common form across the Caribbean, driven by hypertension, diabetes, and cerebrovascular disease. Demonstrates a characteristic stepwise deterioration accompanied by focal neurological signs.
• Dementia with Lewy Bodies (DLB): Core clinical triad of (1) Fluctuating cognition and attention, (2) Recurrent vivid, well-formed visual hallucinations (typically of animals or small people), and (3) Spontaneous parkinsonism. CRITICAL PHARMACOLOGICAL RULE: DLB patients have extreme neuroleptic sensitivity. Administration of conventional typical antipsychotics can precipitate catastrophic irreversible motor rigidity, acute catatonia, autonomic collapse, and mortality.

---

Antipsychotic Pharmacology: Typicals vs. Atypicals

Antipsychotic drugs are broadly divided into First-Generation (Typical) and Second-Generation (Atypical) agents based on their pharmacological receptor binding affinities and motor adverse effect profiles.

First-Generation Antipsychotics (FGAs / Typicals)

• High-Potency FGAs: Haloperidol, fluphenazine, trifluoperazine.
• Low-Potency FGAs: Chlorpromazine, thioridazine.
• Receptor Mechanism: Potent competitive antagonists of dopamine D2 receptors. Clinical antipsychotic response requires approximately 65% to 70% D2 receptor occupancy in the mesolimbic system. However, when occupancy exceeds 80% in the striatum, the threshold for extrapyramidal symptoms and hyperprolactinemia is crossed.
• Efficacy & Adverse Profile: Highly effective against positive psychotic symptoms. Carries high rates of acute dystonic reactions, akathisia, and drug-induced parkinsonism. Low-potency agents have weaker D2 antagonism but strong antihistaminic (sedation), anticholinergic, and alpha-1 adrenergic blocking (orthostatic hypotension) properties.

Second-Generation Antipsychotics (SGAs / Atypicals)

• Agents: Risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone.
• Receptor Mechanism: Potent antagonism of serotonin 5-HT2A receptors coupled with moderate D2 receptor antagonism (or partial D2 agonism in the case of aripiprazole). Serotonin 5-HT2A blockade promotes downstream dopamine release in the nigrostriatal pathway, displacing D2 blockade sufficiently to lower EPS rates, and enhances cortical dopamine to partially improve negative symptoms.
• Metabolic Syndrome & Cardiometabolic Risk: While SGAs dramatically lower motor neurological side effects, they induce severe cardiometabolic dysfunction: rapid weight gain, central adiposity, atherogenic dyslipidemia (hypertriglyceridemia), and insulin resistance predisposing to frank Type 2 diabetes mellitus.
  • Highest Metabolic Risk: Olanzapine and Clozapine.
  • Moderate Metabolic Risk: Risperidone and Quetiapine.
  • Lowest Metabolic Risk (Metabolically Neutral): Aripiprazole (partial D2 agonist) and Ziprasidone (requires baseline ECG monitoring due to concentration-dependent QTc prolongation).

---

Clozapine: Indications, Mandatory Monitoring & Lethal Toxicities

Clozapine is the prototypic second-generation atypical antipsychotic. Despite its unmatched efficacy, its clinical use is strictly circumscribed by severe, life-threatening adverse effects.

Indications for Clozapine

1. Treatment-Resistant Schizophrenia: Defined as persistent, clinically significant positive symptoms despite adequate sequential trials of at least two different antipsychotics (at least one of which must be a second-generation atypical agent) given at therapeutic doses for an adequate duration (at least 6 weeks each).
2. Recurrent Suicidal Behavior: Schizophrenia or schizoaffective patients exhibiting persistent, high-risk suicidal ideation or recurrent suicide attempts.

Major Adverse Effects & Clinical Management

US boxed warnings cover severe neutropenia, orthostatic hypotension/bradycardia/syncope, seizures, myocarditis/cardiomyopathy, and increased mortality in elderly patients with dementia-related psychosis. The important adverse effects below also include bowel hypomotility and hypersalivation.

1. Severe Neutropenia & Agranulocytosis:
   • Occurs in 0.8% to 1.5% of patients, with peak vulnerability during the first 18 weeks of therapy. It is an idiosyncratic, non-dose-dependent immune-mediated destruction of bone marrow granulocyte precursors.
   • ANC Surveillance: Follow the applicable local product/regulatory protocol. For example, the current US algorithm recommends baseline ANC >=1500/uL, or >=1000/uL with documented Duffy-null associated neutrophil count (formerly BEN), and weekly testing for 6 months, every 2 weeks for months 7–12, then monthly. US REMS reporting ended in June 2025; clinical ANC monitoring continues.
   • US Action Thresholds: Without Duffy-null associated neutrophil count, ANC 1000–1499/uL permits continuation with three-times-weekly monitoring; 500–999/uL requires interruption and hematology consultation, with resumption once ANC is >=1000/uL. ANC <500/uL is severe neutropenia: discontinue and obtain urgent hematology/infection assessment. Rechallenge after recovery requires an individualized specialist benefit–risk decision, not an automatic lifelong prohibition. With documented Duffy-null associated neutrophil count, 500–999/uL can permit continuation with hematology advice and intensified monitoring; <500/uL requires discontinuation. Confirm an unexpected low count promptly and assess fever/sepsis urgently.
2. Myocarditis & Cardiomyopathy:
   • Acute eosinophilic myocarditis typically manifests within the first 4 to 8 weeks. Clinical features include persistent resting tachycardia out of proportion to fever, chest pain, dyspnea, palpitations, peripheral edema, or unexplained fever. Baseline and serial monitoring of troponin, CRP, and ECG are standard. Immediate permanent cessation is required if myocarditis is confirmed.
3. Severe Gastrointestinal Hypomotility (Constipation & Paralytic Ileus):
   • Clozapine possesses profound anticholinergic, antiserotonergic, and antihistaminic activity, dramatically slowing intestinal transit. Clozapine-induced paralytic ileus, bowel ischemia, and perforation carry a case fatality rate higher than agranulocytosis. Prophylactic bowel regimens (stimulant laxatives like senna combined with osmotic agents like macrogol/polyethylene glycol) must be initiated concurrently with clozapine titration.
4. Dose-Dependent Seizures:
   • Clozapine significantly lowers the seizure threshold in a dose-dependent fashion, with cumulative risk exceeding 5% at doses > 500-600 mg/day. If seizures occur, reduce clozapine dose and initiate Sodium Valproate as the anticonvulsant of choice. Carbamazepine is strictly avoided due to additive bone marrow suppression.
5. Excessive Sialorrhea (Hypersalivation):
   • Paradoxical nocturnal drooling occurs due to muscarinic M4 receptor agonism and impaired pharyngeal swallowing. Managed clinically with topical sublingual anticholinergic drops (e.g., 1% atropine ophthalmic drops administered sublingually at bedtime) or sublingual ipratropium spray.